Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2309701 | 0.84 | CCR2 (0.39) | CACNA1GSIGMAR1CCR3 | |
| SCHEMBL2380375 | 0.80 | SMN1; SMN2 (0.41) | CACNA1GSIGMAR1 | |
| SCHEMBL2306028 | 0.80 | SIGMAR1 (0.60) | CACNA1GSIGMAR1DRD4 | |
| SCHEMBL2363774 | 0.78 | SIGMAR1 (0.54) | SIGMAR1DRD4 | |
| SCHEMBL2545118 | 0.77 | SIGMAR1 (0.41) | CACNA1GSIGMAR1DRD4CCR3 | |
| SCHEMBL2310361 | 0.77 | TP53 (0.57) | — | |
| SCHEMBL2309716 | 0.77 | CYP2D6 (0.46) | SIGMAR1DRD2 | |
| SCHEMBL2535983 | 0.76 | MAPT (0.44) | — | |
| SCHEMBL2309063 | 0.76 | FAAH (0.50) | DRD4 | |
| SCHEMBL2309233 | 0.75 | SIGMAR1 (0.67) | SIGMAR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | claimed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | claimed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | CACNA1G 10/4885SIGMAR1 676/4885DRD2 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.